The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

BACKGROUND: Patients with locally advanced irresectable or clinically node positive urothelial cancer (UC) have a poor outcome. Currently, these patients can only be cured by receiving induction chemotherapy and, if an adequate radiological response is obtained, radical surgical resection. Long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutten, V. C., Salhi, Y., Robbrecht, G. J., de Wit, R., van Leenders, G. J.L.H., Zuiverloon, T. C.M., Boormans, J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262374/
https://www.ncbi.nlm.nih.gov/pubmed/37312054
http://dx.doi.org/10.1186/s12885-023-10963-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262374/
https://www.ncbi.nlm.nih.gov/pubmed/37312054
http://dx.doi.org/10.1186/s12885-023-10963-7

Ejemplares similares